Kyntra Bio (KYNB) Q2 2024 earnings summary

Executive summary

• Q2 2024 revenue rose 14% year-over-year to $50.6M, driven by strong roxadustat sales in China, offsetting declines from discontinued pamrevlumab programs after negative late-stage pancreatic cancer trial results and leading to a 75% U.S. workforce reduction.

• Strategic focus shifts to FG-3246 (CD46-targeted ADC for mCRPC) and continued expansion of roxadustat, with new clinical milestones and partnering opportunities ahead.

• Net loss narrowed to $15.5M for Q2 2024 from $87.7M in Q2 2023, reflecting higher revenue and significant cost reductions.

• Roxadustat remains the primary value driver, with continued commercial growth in China and ongoing development for chemotherapy-induced anemia.

• Oncology pipeline advanced with FG-3246, while pamrevlumab pancreatic cancer programs were discontinued.

Financial highlights

• Q2 2024 total revenue was $50.6M, up 14% year-over-year; roxadustat China net product revenue was $49.6M, up 108% year-over-year.

• Operating expenses dropped 53% year-over-year to $61.6M; net loss per share improved to $0.16 from $0.90 year-over-year.

• Ended Q2 with $147.1M in cash, cash equivalents, and accounts receivable.

• Roxadustat maintains category leadership in China’s ESA + HIF market based on sales.

• Product revenue from China (mainly Falikang): $49.6M in Q2 2024 (+108% YoY); $80.2M in H1 2024 (+67% YoY).

Outlook and guidance

• Full-year 2024 net product revenue guidance raised to $135M–$150M, with China roxadustat net sales projected at $320M–$350M.

• Operating expenses expected to be $45M–$55M per quarter in H2 2024, excluding restructuring charges.

• Cash runway projected into 2026 based on current balances and operating plans.

• Approval decision for chemotherapy-induced anemia (CIA) SNDA in China anticipated in H2 2024.

• Topline Phase 2 results for FG-3246 + enzalutamide expected in 1H 2025; Phase 2 monotherapy study to initiate in 1Q 2025.